» Articles » PMID: 26756220

Antitumoral Effect of Ocoxin on Acute Myeloid Leukemia

Overview
Journal Oncotarget
Specialty Oncology
Date 2016 Jan 13
PMID 26756220
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Acute myeloid leukemia (AML) is a heterogeneous hematological malignancy whose incidence is growing in developed countries. In the relapse setting, very limited therapeutic options are available and in most cases only palliative care can be offered to patients. The effect of a composite formulation that contains several antioxidants, Ocoxin Oral solution (OOS), was tested in this condition. When analyzed in vitro, OOS exhibited anti-AML action that was both time and dose dependent. In vivo OOS induced a ralentization of tumor growth that was due to a decrease in cell proliferation. Such effect could, at least partially, be due to an increase in the cell cycle inhibitor p27, although other cell cycle proteins seemed to be altered. Besides, OOS induced an immunomodulatory effect through the induction of IL6. When tested in combination with other therapeutic agents normally used in the treatment of AML patients, OOS demonstrated a higher antiproliferative action, suggesting that it may be used in combination with those standard of care treatments to potentiate their antiproliferative action in the AML clinic.

Citing Articles

Ocoxin Oral Solution Triggers DNA Damage and Cell Death in Ovarian Cancer.

Almaraz-Postigo S, Sanz E, Pandiella A, Diaz-Rodriguez E Nutrients. 2024; 16(15).

PMID: 39125297 PMC: 11313973. DOI: 10.3390/nu16152416.


Microenvironmental Reactive Oxygen Species in Colorectal Cancer: Involved Processes and Therapeutic Opportunities.

Sorolla M, Hidalgo I, Sorolla A, Montal R, Pallise O, Salud A Cancers (Basel). 2021; 13(20).

PMID: 34680186 PMC: 8534037. DOI: 10.3390/cancers13205037.


Modelling hypersensitivity to trastuzumab defines biomarkers of response in HER2 positive breast cancer.

Diaz-Gil L, Braso-Maristany F, Locatelli C, Centa A, Gyorffy B, Ocana A J Exp Clin Cancer Res. 2021; 40(1):313.

PMID: 34620206 PMC: 8496101. DOI: 10.1186/s13046-021-02098-z.


Ocoxin oral solution demonstrates antiviral properties in cellular models.

Pandiella A, Sanz E, Diaz-Rodriguez E Exp Ther Med. 2021; 22(4):1127.

PMID: 34504579 PMC: 8383335. DOI: 10.3892/etm.2021.10561.


Ocoxin Increases the Antitumor Effect of BRAF Inhibition and Reduces Cancer Associated Fibroblast-Mediated Chemoresistance and Protumoral Activity in Metastatic Melanoma.

Benedicto A, Hernandez-Unzueta I, Sanz E, Marquez J Nutrients. 2021; 13(2).

PMID: 33669949 PMC: 7924874. DOI: 10.3390/nu13020686.


References
1.
Nicola N, Babon J . Leukemia inhibitory factor (LIF). Cytokine Growth Factor Rev. 2015; 26(5):533-44. PMC: 4581962. DOI: 10.1016/j.cytogfr.2015.07.001. View

2.
Szer J . The prevalent predicament of relapsed acute myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2012; 2012:43-8. DOI: 10.1182/asheducation-2012.1.43. View

3.
Vilar Gomez E, Perez Y, Vega Sanchez H, Forment G, Soler E, Bertot L . Antioxidant and immunomodulatory effects of Viusid in patients with chronic hepatitis C. World J Gastroenterol. 2010; 16(21):2638-47. PMC: 2880777. DOI: 10.3748/wjg.v16.i21.2638. View

4.
Chu I, Blackwell K, Chen S, Slingerland J . The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res. 2005; 65(1):18-25. View

5.
Horak E, Leek R, Klenk N, Lejeune S, Smith K, Stuart N . Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet. 1992; 340(8828):1120-4. DOI: 10.1016/0140-6736(92)93150-l. View